Varian Halcyon Treatment System Receives AERB Certificate for Import & amp; Supply in India

PALO ALTO, Calif. and MUMBAI, India - Feb. 6, 2018 - Varian (NYSE: VAR) today announced the Halcyon™ cancer treatment platform has received Atomic Energy Regulatory Board (AERB) Certificate for Import and Supply in India. This registration allows Varian to now market this new system in India. Halcyon simplifies and enhances virtually every aspect of image-guided volumetric intensity modulated radiotherapy (IMRT), and is well suited to treat a majority of cancer patients, offering...This story is related to the following:Clinical Medical Equipment
Source: Industrial Newsroom - Health, Medical and Dental Supplies - Category: Medical Devices Source Type: news

Related Links:

OBJECTIVE: To analyze the pattern of local failure in patients with nasopharyngeal carcinoma (NPC) after intensity-modulated radiotherapy (IMRT) and find a more reasonable delineation of the clinical target volume (CTV).METHODS AND MATERIALS: A total of 212 patients with non-metastatic NPC who underwent IMRT were analyzed. Radiation therapy was run at a total dose of 66-74 Gy (2.0-2.2 Gy fractions). The follow-up of local recurrence and the recurrence-related features were analyzed for the original treatment situation. The failures were delimited as “in-field failure” if Vrecur within the 95% isodose curve (V95...
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research
Conclusion: For ESCC patients, LCAHFRT delivered by image-guided intensity-modulated techniques Plus Concurrent Chemotherapy with cisplatin and docetaxel keeps safety and high CR rate, as well as local control and long-term survival rates.
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research
Nasopharyngeal carcinoma (NPC) is one of the most common malignant tumors of the head and neck in Southeast Asia and southern China. Although the comprehensive treatment based on intensity-modulated radiation therapy improves outcomes, the five-year survival rate of NPC patients is low, and the recurrence remains high. Radiotherapy resistance is the main cause of poor prognosis in NPC patients. MicroRNAs (miRNAs) are a class of endogenous non-coding RNAs regulating various biological functions in eukaryotes. These miRNAs can regulate the development and progression of nasopharyngeal carcinoma by affecting the proliferation...
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Conclusion: In patients aged 75 years or older with LARC, neoadjuvant chemoradiotherapy followed by surgery was well tolerated with promising survival outcomes, which should be strongly suggested if medically suitable.
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research
Nasopharyngeal carcinoma (NPC) is the malignant tumor with ethnic and geographical distribution preference. Although intensity-modulated radiotherapy (IMRT)-based radiotherapy combined with chemotherapy and targeted therapy has dramatically improved the overall survival of NPC patients, there are still some patients suffering from recurrent tumors and the prognosis is poor. Multiple mechanisms may be responsible for radioresistance of NPC, such as cancer stem cells (CSCs) existence, gene mutation or aberrant expression of genes, epigenetic modification of genes, abnormal activation of certain signaling pathways, alteration...
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
This study demonstrated that after the completion of 3-4 cycles of chemotherapy with a remission, concurrent chemoradiotherapy with oral etoposide and cisplatin improved survival compared with sequential chemoradiotherapy in LS-SCLC with bulky tumor. ClinicalTrials.gov Identifier: NCT01745445.
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research
Conditions:   Nasopharyngeal Carcinoma;   Radiotherapy;   Chemotherapy Interventions:   Radiation: reduced dosage IMRT;   Radiation: conventional dosage IMRT Sponsors:   Sun Yat-sen University;   National Cancer Centre, Singapore;   Affiliated Cancer Hospital&Institute of Guangzhou Medical University;   Zhongshan People's Hospital, Guangdong, China;   Yuebei People's Hospital;   Wuzhou Red Cross Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Radiation therapy remains an essential component of cancer therapy for millions of patients annually in the United States and globally. Radiation therapy involves the focal deposition of ionizing radiation (IR) to the tumor and surrounding at-risk tissue compartments such as regional lymph nodes. The most common treatment approaches include external beam radiation therapy (EBRT) using high-energy photons, electrons, or protons, as well as brachytherapy and radionuclide therapy. Significant technical advances in EBRT and diagnostic imaging over the past several decades have enabled more localized and precise dose deposition...
Source: Radiotherapy and Oncology - Category: Radiology Authors: Tags: Review Article Source Type: research
Condition:   Rectal Cancer Interventions:   Drug: Capecitabine (Xeloda) Pharmacogenetic Test Reagents;   Drug: irinotecan;   Radiation: IMRT;   Drug: Oxaliplatin;   Drug: 5Fluorouracil;   Drug: Tislelizumab Sponsor:   Fudan University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | India Health | Intensity-Modulated Radiation Therapy | Medical Devices